Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing

OBJECTIVE: To determine the onset of preventive efficacy with eptinezumab in patients with migraine. BACKGROUND: Eptinezumab is a monoclonal antibody inhibiting calcitonin gene‐related peptide approved as an intravenously administered treatment for the prevention of migraine. METHODS: Patients who r...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodick, David W., Gottschalk, Christopher, Cady, Roger, Hirman, Joe, Smith, Jeff, Snapinn, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756794/
https://www.ncbi.nlm.nih.gov/pubmed/33165938
http://dx.doi.org/10.1111/head.14007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756794/
https://www.ncbi.nlm.nih.gov/pubmed/33165938
http://dx.doi.org/10.1111/head.14007

Ejemplares similares